drugset / Trial / NCT03597620

Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis

NCT03597620 ↗

Phase 4 Completed 11 enrolled University of Alabama at Birmingham
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Psoriasis vulgaris is a common inflammatory condition of the skin that results in well-demarcated, scaly, erythematous, itchy plaques. In the United States, psoriasis remains a common, immune-mediated disease, affecting 7.4 million adults. Often topical prescription medications are used as first line treatment for moderate psoriasis. Some topical medications have side effects and risk with long time use, thus not ideal for extensive and indefinite amount of time. Conversely, over- the-counter emollient treatments are readily available, safe and potentially efficacious. This study is design to test the safety and efficacy of topical application of the Metaderm product cream. The Metaderm cream is non-prescription, natural product.

Timeline

Start
2018-11-07
Primary completion
2020-10-31
Completion
2022-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Metaderm Unknown — Topical

Indications